First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D ...

for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide ...

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process ...

for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide ...

12 mo at 37 °C Manufacturer Hepatitis B immune globulin (human) Hyperhep B S/D (Bayer) Cumulative exposure for 7 days Manufacturer Hepatitis B vaccine (recombinant) Engerix-B (GlaxoSmithKline ...

ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States,” said Adam Grossman, President and Chief ...